SKYE

SEC source: 0001516551-24-000022 · wk-form4_1709551223.xml · derivative · entry 1

TYLE PRAVEEN · CIK 0001296936 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 35,000

Underlying: Common Stock · 35,000 shares

Expires 2034-03-01

F1 · derivative.exercise_date: The option grant shall be exercisable for a price of $14.56 per option share for ten years from February 29, 2024 and the options will vest in equal monthly installments over the one year period beginning February 29, 2024.

SEC source: 0001516551-24-000027 · wk-form4_1709551460.xml · derivative · entry 1

DALESANDRO MARGARET · CIK 0001208853 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 35,000

Underlying: Common Stock · 35,000 shares

Expires 2034-03-01

F1 · derivative.exercise_date: The option grant shall be exercisable for a price of $14.56 per option share for ten years from February 29, 2024 and the options will vest in equal monthly installments over the one year period beginning February 29, 2024.

SEC source: 0001516551-24-000039 · wk-form4_1709593294.xml · derivative · entry 1

Charych Deborah H. · CIK 0001965700 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 35,000

Underlying: Common Stock · 35,000 shares

Expires 2034-03-01

F1 · derivative.exercise_date: The option grant shall be exercisable for a price of $14.56 per option share for ten years from February 29, 2024 and the options will vest in equal monthly installments over the one year period beginning February 29, 2024.

SEC source: 0001516551-24-000038 · wk-form4_1709593247.xml · derivative · entry 1

Jenkins Annalisa · CIK 0001639481 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 40,000

Underlying: Common Stock · 40,000 shares

Expires 2034-03-01

F1 · derivative.exercise_date: The option grant shall be exercisable for a price of $14.56 per option share for ten years from February 29, 2024 and the options will vest in equal monthly installments over the one year period beginning February 29, 2024.

SEC source: 0001516551-24-000030 · wk-form4_1709586211.xml · derivative · entry 1

Schwab Andrew J. · CIK 0001598549 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 35,000

Underlying: Common Stock · 35,000 shares

Expires 2034-03-01

F1 · derivative.exercise_date: The option grant shall be exercisable for a price of $14.56 per option share for ten years from February 29, 2024 and the options will vest in equal monthly installments over the one year period beginning February 29, 2024.

SEC source: 0001516551-24-000025 · wk-form4_1709551390.xml · derivative · entry 1

Ward Keith Wayne · CIK 0001662394 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 35,000

Underlying: Common Stock · 35,000 shares

Expires 2034-03-01

F1 · derivative.exercise_date: The option grant shall be exercisable for a price of $14.56 per option share for ten years from February 29, 2024 and the options will vest in equal monthly installments over the one year period beginning February 29, 2024.

SEC source: 0001209191-24-002643 · doc4.xml · nonDerivative · entry 1

5AM Partners VII, LLC · CIK 0001873545 · 10% owner

5AM Ventures VII, L.P. · CIK 0001844435 · 10% owner

5AM Partners II, LLC · CIK 0001555952 · 10% owner

5AM Ventures II LP · CIK 0001386509 · 10% owner

5AM CO-INVESTORS II LP · CIK 0001390376 · 10% owner

DIEKMAN JOHN D · CIK 0001240357 · 10% owner

PARMAR KUSH · CIK 0001664281 · 10% owner

ROCKLAGE SCOTT M · CIK 0001219014 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · By 5AM Ventures VII, L.P.

Disclosed balance after: 7,943,520

F1 · ownership.nature: The securities are directly held by 5AM Ventures VII, L.P. ("Ventures VII"). 5AM Partners VII, LLC ("Partners VII") is the sole general partner of Ventures VII. Dr. Kush Parmar and Andrew J. Schwab are the managing members of Partners VII and may be deemed to have shared voting and investment power over the securities beneficially owned by Ventures VII. Each of Partners VII and Dr. Parmar disclaims beneficial ownership of such securities except to the extent of its or his respective pecuniary interest therein. Mr. Schwab is a director of the Issuer and files separate Section 16 reports.

SEC source: 0001209191-24-002649 · doc4.xml · nonDerivative · entry 1

Schwab Andrew J. · CIK 0001598549 · Director · 10% owner

10b5-1 filing: No plan indicated

Ownership: Indirect · By 5AM Ventures VII, L.P.

Disclosed balance after: 7,943,520

F1 · ownership.nature: The securities are directly held by 5AM Ventures VII, L.P. ("Ventures VII"). 5AM Partners VII, LLC ("Partners VII") is the sole general partner of Ventures VII. The Reporting Person is a managing member of Partners VII and may be deemed to have shared voting and investment power over the shares beneficially owned by Ventures VII. The Reporting Person disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein.

SEC source: 0001516551-23-000096 · wk-form4_1699320590.xml · derivative · entry 2

ARSENAULT KAITLYN · CIK 0001877242 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 45,436

Underlying: Common Stock · 32,053 shares

Expires 2033-08-25

F3 · derivative.exercise_date: The option grant shall be exercisable for a price of $3.50 per option share for ten years from August 25, 2023 and the options will vest in equal monthly installments over the four year period beginning August 24, 2023. Upon a change in control of the Issuer, 100% of the options will become fully vested.

SEC source: 0001516551-23-000096 · wk-form4_1699320590.xml · nonDerivative · entry 1

ARSENAULT KAITLYN · CIK 0001877242 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 185,738

F1 · shares: Represents a restricted stock unit ("RSU") award that vests on the following performance milestones : 25% vests upon achieving a market cap of $125M, an additional 25% vests upon achieving a market cap of $250M, an additional 25% vests upon achieving a market cap of $400M, an additional 25% vest at an exit of $500M or greater; provided, however, that no RSUs shall vest until the compensation committee of the Issuer determines that shares can be sold into the market to cover withholding tax obligations associated with the vesting of the RSUs. Notwithstanding anything to the foregoing, all of the RSUS shall vest if an exit greater than $500M is achieved at an earlier date.

F2 · price: Each RSU represents a contingent right to receive one share of the Issuer's common stock.

SEC source: 0001516551-23-000093 · wk-form4_1699320557.xml · nonDerivative · entry 1

Grayson Paul A. · CIK 0001861554 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 246,252

F1 · shares: Represents a restricted stock unit ("RSU") award that vests on the following performance milestones : 25% vests upon achieving a market cap of $125M, an additional 25% vests upon achieving a market cap of $250M, an additional 25% vests upon achieving a market cap of $400M, an additional 25% vest at an exit of $500M or greater; provided, however, that no RSUs shall vest until the compensation committee of the Issuer determines that shares can be sold into the market to cover withholding tax obligations associated with the vesting of the RSUs. Notwithstanding anything to the foregoing, all of the RSUS shall vest if an exit greater than $500M is achieved at an earlier date.

F2 · price: Each RSU represents a contingent right to receive one share of the Issuer's common stock.

SEC source: 0001516551-23-000095 · wk-form4_1699320579.xml · derivative · entry 2

DHILLON PUNIT · CIK 0001425052 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 30,599

Underlying: Common Stock · 21,586 shares

Expires 2033-08-25

F3 · derivative.exercise_date: The option grant shall be exercisable for a price of $3.50 per option share for ten years from August 25, 2023 and the options will vest in equal monthly installments over the four year period beginning August 24, 2023. Upon a change in control of the Issuer, 100% of the options will become fully vested.

SEC source: 0001516551-23-000095 · wk-form4_1699320579.xml · nonDerivative · entry 1

DHILLON PUNIT · CIK 0001425052 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 297,006

F1 · shares: Represents a restricted stock unit ("RSU") award that vests on the following performance milestones : 25% vests upon achieving a market cap of $125M, an additional 25% vests upon achieving a market cap of $250M, an additional 25% vests upon achieving a market cap of $400M, an additional 25% vest at an exit of $500M or greater; provided, however, that no RSUs shall vest until the compensation committee of the Issuer determines that shares can be sold into the market to cover withholding tax obligations associated with the vesting of the RSUs. Notwithstanding anything to the foregoing, all of the RSUS shall vest if an exit greater than $500M is achieved at an earlier date.

F2 · price: Each RSU represents a contingent right to receive one share of the Issuer's common stock.

SEC source: 0001516551-23-000092 · wk-form4_1699320545.xml · derivative · entry 1

TYLE PRAVEEN · CIK 0001296936 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 20,001

Underlying: Common Stock · 14,110 shares

Expires 2033-08-25

F1 · derivative.exercise_date: The option grant shall be exercisable for a price of $3.50 per option share for ten years from August 25, 2023 and the options will vest in equal monthly installments over the one year period beginning August 24, 2023.

SEC source: 0001516551-23-000094 · wk-form4_1699320568.xml · derivative · entry 1

DALESANDRO MARGARET · CIK 0001208853 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 20,001

Underlying: Common Stock · 14,110 shares

Expires 2033-08-25

F1 · derivative.exercise_date: The option grant shall be exercisable for a price of $3.50 per option share for ten years from August 25, 2023 and the options will vest in equal monthly installments over the one year period beginning August 24, 2023.

SEC source: 0001516551-23-000098 · wk-form4_1699320737.xml · derivative · entry 1

Ward Keith Wayne · CIK 0001662394 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 20,001

Underlying: Common Stock · 14,110 shares

Expires 2033-08-25

F1 · derivative.exercise_date: The option grant shall be exercisable for a price of $3.50 per option share for ten years from August 25, 2023 and the options will vest in equal monthly installments over the one year period beginning August 24, 2023.

SEC source: 0001516551-23-000097 · wk-form4_1699320601.xml · derivative · entry 1

Charych Deborah H. · CIK 0001965700 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 20,001

Underlying: Common Stock · 14,110 shares

Expires 2033-08-25

F1 · derivative.exercise_date: The option grant shall be exercisable for a price of $3.50 per option share for ten years from August 25, 2023 and the options will vest in equal monthly installments over the one year period beginning August 24, 2023.

SEC source: 0001516551-23-000091 · wk-form4_1699320532.xml · derivative · entry 1

Schwab Andrew J. · CIK 0001598549 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 20,001

Underlying: Common Stock · 14,110 shares

Expires 2033-08-25

F1 · derivative.exercise_date: The option grant shall be exercisable for a price of $3.50 per option share for ten years from August 25, 2023 and the options will vest in equal monthly installments over the one year period beginning August 24, 2023.

SEC source: 0001516551-23-000062 · wk-form4_1693348773.xml · nonDerivative · entry 4

DHILLON PUNIT · CIK 0001425052 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 41,554,828

SEC source: 0001516551-23-000069 · wk-form4a_1693495603.xml · nonDerivative · entry 4

DHILLON PUNIT · CIK 0001425052 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 25,683,957

SEC source: 0001516551-23-000062 · wk-form4_1693348773.xml · nonDerivative · entry 3

DHILLON PUNIT · CIK 0001425052 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 40,673,828

SEC source: 0001516551-23-000069 · wk-form4a_1693495603.xml · nonDerivative · entry 3

DHILLON PUNIT · CIK 0001425052 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 24,802,957

SEC source: 0001516551-23-000064 · wk-form4_1693349578.xml · derivative · entry 2

ARSENAULT KAITLYN · CIK 0001877242 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 3,345,530

Underlying: Common Stock · 3,345,530 shares

Expires 2033-08-25

F3 · derivative.exercise_date: The option grant shall be exercisable for a price of $0.014 per option share for ten years from August 25, 2023 and the options will vest in equal monthly installments over the four year period beginning August 24, 2023. Upon a change in control of the Issuer, 100% of the options will become fully vested.

SEC source: 0001516551-23-000064 · wk-form4_1693349578.xml · nonDerivative · entry 1

ARSENAULT KAITLYN · CIK 0001877242 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 14,382,118

F1 · shares: Represents a restricted stock unit ("RSU") award that vests on the following performance milestones : 25% vests upon achieving a market cap of $125M, an additional 25% vests upon achieving a market cap of $250M, an additional 25% vests upon achieving a market cap of $400M, an additional 25% vest at an exit of $500M or greater; provided, however, that no RSUs shall vest until the compensation committee of the Issuer determines that shares can be sold into the market to cover withholding tax obligations associated with the vesting of the RSUs . Notwithstanding anything to the foregoing, all of the RSUS shall vest if an exit greater than $500M is achieved at an earlier date.

F2 · price: Each RSU represents a contingent right to receive one share of the Issuer's common stock.

SEC source: 0001516551-23-000066 · wk-form4_1693351547.xml · nonDerivative · entry 1

Grayson Paul A. · CIK 0001861554 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 18,132,596

F1 · shares: Represents a restricted stock unit ("RSU") award that vests on the following performance milestones : 25% vests upon achieving a market cap of $125M, an additional 25% vests upon achieving a market cap of $250M, an additional 25% vests upon achieving a market cap of $400M, an additional 25% vest at an exit of $500M or greater; provided, however, that no RSUs shall vest until the compensation committee of the Issuer determines that shares can be sold into the market to cover withholding tax obligations associated with the vesting of the RSUs . Notwithstanding anything to the foregoing, all of the RSUS shall vest if an exit greater than $500M is achieved at an earlier date.

F2 · price: Each RSU represents a contingent right to receive one share of the Issuer's common stock.

SEC source: 0001516551-23-000062 · wk-form4_1693348773.xml · derivative · entry 5

DHILLON PUNIT · CIK 0001425052 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,253,046

Underlying: Common Stock · 2,253,046 shares

Expires 2033-08-25

F3 · derivative.exercise_date: The option grant shall be exercisable for a price of $0.014 per option share for ten years from August 25, 2023 and the options will vest in equal monthly installments over the four year period beginning August 24, 2023. Upon a change in control of the Issuer, 100% of the options will become fully vested.

SEC source: 0001516551-23-000062 · wk-form4_1693348773.xml · nonDerivative · entry 1

DHILLON PUNIT · CIK 0001425052 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 40,554,828

F1 · shares: Represents a restricted stock unit ("RSU") award that vests on the following performance milestones : 25% vests upon achieving a market cap of $125M, an additional 25% vests upon achieving a market cap of $250M, an additional 25% vests upon achieving a market cap of $400M, an additional 25% vest at an exit of $500M or greater; provided, however, that no RSUs shall vest until the compensation committee of the Issuer determines that shares can be sold into the market to cover withholding tax obligations associated with the vesting of the RSUs . Notwithstanding anything to the foregoing, all of the RSUS shall vest if an exit greater than $500M is achieved at an earlier date.

F2 · price: Each RSU represents a contingent right to receive one share of the Issuer's common stock.

SEC source: 0001516551-23-000060 · wk-form4_1693347739.xml · derivative · entry 1

TYLE PRAVEEN · CIK 0001296936 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,472,692

Underlying: Common Stock · 1,472,692 shares

Expires 2033-08-25

F1 · derivative.exercise_date: The option grant shall be exercisable for a price of $0.014 per option share for ten years from August 25, 2023 and the options will vest in equal monthly installments over the one year period beginning August 24, 2023.

SEC source: 0001516551-23-000058 · wk-form4_1693347662.xml · derivative · entry 1

DALESANDRO MARGARET · CIK 0001208853 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,472,692

Underlying: Common Stock · 1,472,692 shares

Expires 2033-08-25

F1 · derivative.exercise_date: The option grant shall be exercisable for a price of $0.014 per option share for ten years from August 25, 2023 and the options will vest in equal monthly installments over the one year period beginning August 24, 2023.

SEC source: 0001516551-23-000068 · wk-form4_1693359362.xml · derivative · entry 1

Schwab Andrew J. · CIK 0001598549 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,472,692

Underlying: Common Stock · 1,472,692 shares

Expires 2033-08-25

F1 · derivative.exercise_date: The option grant shall be exercisable for a price of $0.014 per option share for ten years from August 25, 2023 and the options will vest in equal monthly installments over the one year period beginning August 24, 2023.

SEC source: 0001516551-23-000056 · wk-form4_1693347437.xml · derivative · entry 1

Ward Keith Wayne · CIK 0001662394 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,472,692

Underlying: Common Stock · 1,472,692 shares

Expires 2033-08-25

F1 · derivative.exercise_date: The option grant shall be exercisable for a price of $0.014 per option share for ten years from August 25, 2023 and the options will vest in equal monthly installments over the one year period beginning August 24, 2023.

SEC source: 0001516551-23-000054 · wk-form4_1693346510.xml · derivative · entry 1

Charych Deborah H. · CIK 0001965700 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,472,692

Underlying: Common Stock · 1,472,692 shares

Expires 2033-08-25

F1 · derivative.exercise_date: The option grant shall be exercisable for a price of $0.014 per option share for ten years from August 25, 2023 and the options will vest in equal monthly installments over the one year period beginning August 24, 2023.

SEC source: 0001516551-23-000069 · wk-form4a_1693495603.xml · derivative · entry 6

DHILLON PUNIT · CIK 0001425052 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,253,046

Underlying: Common Stock · 2,253,046 shares

Expires 2033-08-25

F4 · derivative.exercise_date: The option grant shall be exercisable for a price of $0.014 per option share for ten years from August 25, 2023 and the options will vest in equal monthly installments over the four year period beginning August 24, 2023. Upon a change in control of the Issuer, 100% of the options will become fully vested.

SEC source: 0001516551-23-000069 · wk-form4a_1693495603.xml · nonDerivative · entry 1

DHILLON PUNIT · CIK 0001425052 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 24,683,957

F1 · shares: Represents a restricted stock unit ("RSU") award that vests on the following performance milestones : 25% vests upon achieving a market cap of $125M, an additional 25% vests upon achieving a market cap of $250M, an additional 25% vests upon achieving a market cap of $400M, an additional 25% vest at an exit of $500M or greater; provided, however, that no RSUs shall vest until the compensation committee of the Issuer determines that shares can be sold into the market to cover withholding tax obligations associated with the vesting of the RSUs . Notwithstanding anything to the foregoing, all of the RSUS shall vest if an exit greater than $500M is achieved at an earlier date.

F2 · price: Each RSU represents a contingent right to receive one share of the Issuer's common stock.

SEC source: 0001516551-23-000062 · wk-form4_1693348773.xml · nonDerivative · entry 2

DHILLON PUNIT · CIK 0001425052 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 40,563,828

SEC source: 0001516551-23-000069 · wk-form4a_1693495603.xml · nonDerivative · entry 2

DHILLON PUNIT · CIK 0001425052 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 24,692,957

SEC source: 0001516551-23-000052 · wk-form4_1692739248.xml · derivative · entry 6

Schwab Andrew J. · CIK 0001598549 · Director · 10% owner

10b5-1 filing: No plan indicated

Ownership: Indirect · By 5AM Ventures VII, L.P.

Disclosed balance after: 426,348,120

Underlying: Common Stock · 426,348,120 shares

Expires 2033-08-18

F4 · price: The securities were purchased pursuant to a Securities Purchase Agreement, dated as of August 15, 2023 (the "Purchase Agreement"). The transactions contemplated by the Purchase Agreement closed concurrently with the Merger on August 18, 2023. Pursuant to the Purchase Agreement, 5AM Ventures VII, L.P. ("Ventures VII") purchased an aggregate of 852,696,240 shares of common stock (of which Ventures II and Co-Investors II were allocated 161,944,872 shares and 6,389,799 shares, respectively) for the total purchase price of $8.8 million and received warrants to purchase an aggregate of 426,348,120 shares of common stock for no additional consideration.

F5 · ownership.nature: The securities are directly held by 5AM Ventures VII, L.P. ("Ventures VII"). 5AM Partners VII, LLC ("Partners VII") is the sole general partner of Ventures VII. The Reporting Person is a managing member of Partners VII and may be deemed to have shared voting and investment power over the shares beneficially owned by Ventures VII. The Reporting Person disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein.

SEC source: 0001516551-23-000052 · wk-form4_1692739248.xml · nonDerivative · entry 5

Schwab Andrew J. · CIK 0001598549 · Director · 10% owner

10b5-1 filing: No plan indicated

Ownership: Indirect · By 5AM Co-Investors II, L.P.

Disclosed balance after: 16,948,799

F4 · shares: The securities were purchased pursuant to a Securities Purchase Agreement, dated as of August 15, 2023 (the "Purchase Agreement"). The transactions contemplated by the Purchase Agreement closed concurrently with the Merger on August 18, 2023. Pursuant to the Purchase Agreement, 5AM Ventures VII, L.P. ("Ventures VII") purchased an aggregate of 852,696,240 shares of common stock (of which Ventures II and Co-Investors II were allocated 161,944,872 shares and 6,389,799 shares, respectively) for the total purchase price of $8.8 million and received warrants to purchase an aggregate of 426,348,120 shares of common stock for no additional consideration.

F4 · price: The securities were purchased pursuant to a Securities Purchase Agreement, dated as of August 15, 2023 (the "Purchase Agreement"). The transactions contemplated by the Purchase Agreement closed concurrently with the Merger on August 18, 2023. Pursuant to the Purchase Agreement, 5AM Ventures VII, L.P. ("Ventures VII") purchased an aggregate of 852,696,240 shares of common stock (of which Ventures II and Co-Investors II were allocated 161,944,872 shares and 6,389,799 shares, respectively) for the total purchase price of $8.8 million and received warrants to purchase an aggregate of 426,348,120 shares of common stock for no additional consideration.

F3 · ownership.nature: The securities are directly held by 5AM Co-Investors II, L.P. ("Co-Investors II"). Partners II is the sole general partner of Co-Investors II. The Reporting Person is a managing member of Partners II and may be deemed to have shared voting and investment power over the shares beneficially owned by Co-Investors II. The Reporting Person disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein.

SEC source: 0001516551-23-000052 · wk-form4_1692739248.xml · nonDerivative · entry 4

Schwab Andrew J. · CIK 0001598549 · Director · 10% owner

10b5-1 filing: No plan indicated

Ownership: Indirect · By 5AM Ventures II, L.P.

Disclosed balance after: 429,546,911

F4 · shares: The securities were purchased pursuant to a Securities Purchase Agreement, dated as of August 15, 2023 (the "Purchase Agreement"). The transactions contemplated by the Purchase Agreement closed concurrently with the Merger on August 18, 2023. Pursuant to the Purchase Agreement, 5AM Ventures VII, L.P. ("Ventures VII") purchased an aggregate of 852,696,240 shares of common stock (of which Ventures II and Co-Investors II were allocated 161,944,872 shares and 6,389,799 shares, respectively) for the total purchase price of $8.8 million and received warrants to purchase an aggregate of 426,348,120 shares of common stock for no additional consideration.

F4 · price: The securities were purchased pursuant to a Securities Purchase Agreement, dated as of August 15, 2023 (the "Purchase Agreement"). The transactions contemplated by the Purchase Agreement closed concurrently with the Merger on August 18, 2023. Pursuant to the Purchase Agreement, 5AM Ventures VII, L.P. ("Ventures VII") purchased an aggregate of 852,696,240 shares of common stock (of which Ventures II and Co-Investors II were allocated 161,944,872 shares and 6,389,799 shares, respectively) for the total purchase price of $8.8 million and received warrants to purchase an aggregate of 426,348,120 shares of common stock for no additional consideration.

F2 · ownership.nature: The securities are directly held by 5AM Ventures II, L.P. ("Ventures II"). 5AM Partners II, LLC ("Partners II") is the sole general partner of Ventures II. The Reporting Person is a managing member of Partners II and may be deemed to have shared voting and investment power over the shares beneficially owned by Ventures II. The Reporting Person disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein.

SEC source: 0001516551-23-000052 · wk-form4_1692739248.xml · nonDerivative · entry 3

Schwab Andrew J. · CIK 0001598549 · Director · 10% owner

10b5-1 filing: No plan indicated

Ownership: Indirect · By 5AM Ventures VII, L.P.

Disclosed balance after: 684,361,447

F4 · shares: The securities were purchased pursuant to a Securities Purchase Agreement, dated as of August 15, 2023 (the "Purchase Agreement"). The transactions contemplated by the Purchase Agreement closed concurrently with the Merger on August 18, 2023. Pursuant to the Purchase Agreement, 5AM Ventures VII, L.P. ("Ventures VII") purchased an aggregate of 852,696,240 shares of common stock (of which Ventures II and Co-Investors II were allocated 161,944,872 shares and 6,389,799 shares, respectively) for the total purchase price of $8.8 million and received warrants to purchase an aggregate of 426,348,120 shares of common stock for no additional consideration.

F4 · price: The securities were purchased pursuant to a Securities Purchase Agreement, dated as of August 15, 2023 (the "Purchase Agreement"). The transactions contemplated by the Purchase Agreement closed concurrently with the Merger on August 18, 2023. Pursuant to the Purchase Agreement, 5AM Ventures VII, L.P. ("Ventures VII") purchased an aggregate of 852,696,240 shares of common stock (of which Ventures II and Co-Investors II were allocated 161,944,872 shares and 6,389,799 shares, respectively) for the total purchase price of $8.8 million and received warrants to purchase an aggregate of 426,348,120 shares of common stock for no additional consideration.

F5 · ownership.nature: The securities are directly held by 5AM Ventures VII, L.P. ("Ventures VII"). 5AM Partners VII, LLC ("Partners VII") is the sole general partner of Ventures VII. The Reporting Person is a managing member of Partners VII and may be deemed to have shared voting and investment power over the shares beneficially owned by Ventures VII. The Reporting Person disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein.

SEC source: 0001516551-23-000052 · wk-form4_1692739248.xml · nonDerivative · entry 2

Schwab Andrew J. · CIK 0001598549 · Director · 10% owner

10b5-1 filing: No plan indicated

Ownership: Indirect · By 5AM Co-Investors II, L.P.

Disclosed balance after: 10,558,878

F1 · price: Pursuant to the Agreement and Plan of Merger and Reorganization, dated as of August 15, 2023 (the "Merger Agreement"), by and among the Issuer, Bird Rock Bio, Inc. ("Bird Rock Bio") and Aquila Merger Sub, Inc. ("Merger Sub"), Merger Sub merged with and into Bird Rock Bio (the "Merger"), with Bird Rock Bio surviving the Merger as a wholly-owned subsidiary of the Issuer. Upon the closing of the Merger, each share of Bird Rock Bio's Series A preferred stock, Series B preferred stock and Series C preferred stock was converted into the right to receive 18.560295 shares of the Issuer's common stock. The Merger closed on August 18, 2023.

F3 · ownership.nature: The securities are directly held by 5AM Co-Investors II, L.P. ("Co-Investors II"). Partners II is the sole general partner of Co-Investors II. The Reporting Person is a managing member of Partners II and may be deemed to have shared voting and investment power over the shares beneficially owned by Co-Investors II. The Reporting Person disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein.

SEC source: 0001516551-23-000052 · wk-form4_1692739248.xml · nonDerivative · entry 1

Schwab Andrew J. · CIK 0001598549 · Director · 10% owner

10b5-1 filing: No plan indicated

Ownership: Indirect · By 5AM Ventures II, L.P.

Disclosed balance after: 267,602,039

F1 · price: Pursuant to the Agreement and Plan of Merger and Reorganization, dated as of August 15, 2023 (the "Merger Agreement"), by and among the Issuer, Bird Rock Bio, Inc. ("Bird Rock Bio") and Aquila Merger Sub, Inc. ("Merger Sub"), Merger Sub merged with and into Bird Rock Bio (the "Merger"), with Bird Rock Bio surviving the Merger as a wholly-owned subsidiary of the Issuer. Upon the closing of the Merger, each share of Bird Rock Bio's Series A preferred stock, Series B preferred stock and Series C preferred stock was converted into the right to receive 18.560295 shares of the Issuer's common stock. The Merger closed on August 18, 2023.

F2 · ownership.nature: The securities are directly held by 5AM Ventures II, L.P. ("Ventures II"). 5AM Partners II, LLC ("Partners II") is the sole general partner of Ventures II. The Reporting Person is a managing member of Partners II and may be deemed to have shared voting and investment power over the shares beneficially owned by Ventures II. The Reporting Person disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein.

SEC source: 0001567619-23-005234 · doc1.xml · derivative · entry 7

Emerald Health Sciences Inc. · CIK 0001728413 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 2,500,000 shares

Expires 2024-03-29

F2 · kind: Aggregate exercise price for the warrants was paid through a reduction in the debt Issuer owed to Reporting Person under the Multi Draw Credit Facility.

SEC source: 0001567619-23-005234 · doc1.xml · derivative · entry 6

Emerald Health Sciences Inc. · CIK 0001728413 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 2,500,000 shares

Expires 2024-02-01

F2 · kind: Aggregate exercise price for the warrants was paid through a reduction in the debt Issuer owed to Reporting Person under the Multi Draw Credit Facility.

SEC source: 0001567619-23-005234 · doc1.xml · derivative · entry 5

Emerald Health Sciences Inc. · CIK 0001728413 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 2,500,000 shares

Expires 2023-11-01

SEC source: 0001567619-23-005234 · doc1.xml · derivative · entry 4

Emerald Health Sciences Inc. · CIK 0001728413 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 9,141,486 shares

Expires 2024-12-30

SEC source: 0001567619-23-005234 · doc1.xml · nonDerivative · entry 2

Emerald Health Sciences Inc. · CIK 0001728413 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 169,407,901

SEC source: 0001567619-23-005234 · doc1.xml · nonDerivative · entry 1

Emerald Health Sciences Inc. · CIK 0001728413 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 128,028,737

SEC source: 0001516551-23-000022 · wf-form4_167658660353462.xml · derivative · entry 1

Charych Deborah H. · CIK 0001965700 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 250,000

Underlying: Common Stock · 250,000 shares

Expires 2033-02-14

F1 · derivative.exercise_date: 1. The option grant shall be exercisable for a price of $0.039 per option share for ten years from February 14, 2023 and the options will vest in equal monthly installments over the one year period beginning February 15, 2023.

SEC source: 0001516551-23-000006 · wf-form4_167304366212912.xml · derivative · entry 1

TYLE PRAVEEN · CIK 0001296936 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 250,000

Underlying: Common Stock · 250,000 shares

Expires 2033-01-05

F1 · derivative.exercise_date: The option grant shall be exercisable for a price of $0.017 per option share for ten years from January 5, 2023 (the "Grant Date") and the options will vest in equal monthly installments over the one year period from the Grant Date.